All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

Bavarian Nordic Chikungunya Vaccine Recommended by CDC's ACIP

April 18, 2025
By Patrick Lavery
News
Article

The recombinant vaccine, under the brand name Vimkunya, is recommended for persons age 12 and older who are traveling to a country or territory where there is a chikungunya outbreak.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

The United States Centers for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization Practices (ACIP) has recommended Bavarian Nordic’s recombinant vaccine for the prevention of disease caused by chikungunya virus (1). Bavarian Nordic, which is based in Denmark, reported the recommendation of the virus-like particle (VLP)-based, single-dose injection (brand name Vimkunya) on April 16, 2025.

The recombinant chikungunya vaccine was previously approved by FDA in February 2025 for use in individuals age 12 and older, the same group for which ACIP’s recommendation was made (1,2). It had also been recommended for marketing authorization by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency at CHMP’s January 2025 meeting (3).

ACIP has recommended the vaccine for those, again, age 12 and older, who may be traveling to a country or territory where there is a chikungunya outbreak (1). It also may be considered for persons who are traveling or residing in a locale without an outbreak, but where there is elevated risk for US travelers if their stay is planned for an extended length of time.

“ACIP’s recommendation of our chikungunya vaccine for Americans aged 12 and older is a big step forward to expanding access to this vaccine in the United States,” Paul Chaplin, president and CEO of Bavarian Nordic, said in a company press release (1). “Chikungunya is an emerging public health threat around the world, and today’s decision is another milestone in our mission to protect more people from this virus.”

The disease known as chikungunya is mosquito-borne and is caused by the virus of the same name (1). It has been identified in more than 110 countries in the past two decades, including numerous travel destinations in Asia, Africa, and the Americas, and evidence of transmission has been observed in more than 50 countries since 2020. Bavarian Nordic characterizes outbreaks as often large and unpredictable.

Symptoms usually include fever, rash, fatigue, headache and often, according to Bavarian Nordic, severe, incapacitating joint pain (1). While most patients recover in one to two weeks, up to 40% of those with the disease have the chance of developing months- or yearslong chronic arthritis. Worldwide chikungunya cases were reported to have increased by more than 20% in 2024 over 2023, equating to approximately 620,000 diagnoses. However, Bavarian Nordic said data has suggested that case numbers are “severely” underreported, with many misdiagnosed as dengue fever (1).

ACIP’s recommendation is pending final approval by the director of the CDC, and by the US Department of Health and Human Services. The Bavarian Nordic vaccine is supplied in a single-dose, 1-mL glass pre-filled syringe, with a dose volume of 0.8 mL (1).

References

1. Bavarian Nordic. Bavarian Nordic’s Chikungunya Vaccine Receives Recommendation from US CDC’s Advisory Committee on Immunization Practices (ACIP). Press Release. March 16, 2025.
2. Bavarian Nordic. Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older. Press Release. Feb. 14, 2025.
3. EMA. Meeting Highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 January 2025. Press Release. Jan. 31, 2025.

Recent Videos
Behind the Headlines, Episode 18
Behind the Headlines, Episode 18: Sanofi, GSK Go Big in M&A, mRNA Momentum Falters, and More
A CDMO’s Role in API Quality
A CDMO’s Role in API Quality
CPHI Americas 2025: The Evolving Role of the CDMO
CPHI Americas 2025: The Evolving Role of the CDMO
Drug Digest: Patient Preference Drives Solid Dosage Trends
Drug Digest: Patient Preference Drives Solid Dosage Trends
Ask the Expert: Quality Control Units
Ask the Expert: Quality Control Units
Behind the Headlines, Episode 17
Behind the Headlines, Episode 17: Bespoke CRISPR Therapy, Executive Order Fallout, and More
Industry Outlook 2025: European Political Impacts on the Supply Chain
Industry Outlook 2025: European Political Impacts on the Supply Chain
AAPS National Biotechnology Conference 2025: High-Concentration Biologics
AAPS National Biotechnology Conference 2025: High-Concentration Biologics
Industry Outlook 2025: The Future of Technology in the Biopharma Industry
Industry Outlook 2025: The Future of Technology in the Biopharma Industry
AAPS National Biotechnology Conference 2025: AAV Vector Production
AAPS National Biotechnology Conference 2025: AAV Vector Production
Related Content
Advertisement

Three groups of people are connected by lines. Coordination and knowledge sharing. Outsourcing. | Image Credit: © Uladzislau - stock.adobe.com

Market Demands and Emerging Technologies Shape Outsourcing Models

Patrick Lavery
June 5th 2025
Article

Trends in certain forms of drug delivery, as well as the emergence of artificial intelligence, are playing roles in evolving the nature of partnerships, but there are new types of partnerships gaining steam as well.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


Landkarte *** Europa | Image credit: ©beugdesign - Stock.adobe.com

EMA Is Tackling Vulnerabilities in the Supply Chain of Radiopharmaceuticals

Cheryl Barton
June 4th 2025
Article

EMA has published recommendations to address potential radiopharmaceutical shortages.


Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.


Question mark background | Image Credit: © Leigh-Prather - © Leigh Prather - stock.adobe.com

Guidance on Quality Culture Standards

Matt Cushing;Susan J. Schniepp
June 3rd 2025
Article

Matt Cushing, VP of Quality and Science, Nelson Labs, and Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, a Nelson Labs Company, discuss PDA/ANSI Standard 06-2025: Assessment of Quality Culture Guidance Documents, Models, and Tools, which was published in February 2025.


inscription on the courthouse | Image Credit: © bluraz - stock.adobe.com

Eisai Wins Judgment Against Shilpa Over Sale of Lenvatinib Mesylate Generic

Patrick Lavery
June 2nd 2025
Article

As a result of the decision, Shilpa will not be eligible to receive FDA approval for its lenvatinib mesylate generic until February 2036.

Related Content
PharmTech News
|
Quality Systems
|
Regulatory Oversight and Compliance
Advertisement

Three groups of people are connected by lines. Coordination and knowledge sharing. Outsourcing. | Image Credit: © Uladzislau - stock.adobe.com

Market Demands and Emerging Technologies Shape Outsourcing Models

Patrick Lavery
June 5th 2025
Article

Trends in certain forms of drug delivery, as well as the emergence of artificial intelligence, are playing roles in evolving the nature of partnerships, but there are new types of partnerships gaining steam as well.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


Landkarte *** Europa | Image credit: ©beugdesign - Stock.adobe.com

EMA Is Tackling Vulnerabilities in the Supply Chain of Radiopharmaceuticals

Cheryl Barton
June 4th 2025
Article

EMA has published recommendations to address potential radiopharmaceutical shortages.


Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.


Question mark background | Image Credit: © Leigh-Prather - © Leigh Prather - stock.adobe.com

Guidance on Quality Culture Standards

Matt Cushing;Susan J. Schniepp
June 3rd 2025
Article

Matt Cushing, VP of Quality and Science, Nelson Labs, and Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, a Nelson Labs Company, discuss PDA/ANSI Standard 06-2025: Assessment of Quality Culture Guidance Documents, Models, and Tools, which was published in February 2025.


inscription on the courthouse | Image Credit: © bluraz - stock.adobe.com

Eisai Wins Judgment Against Shilpa Over Sale of Lenvatinib Mesylate Generic

Patrick Lavery
June 2nd 2025
Article

As a result of the decision, Shilpa will not be eligible to receive FDA approval for its lenvatinib mesylate generic until February 2036.

Advertisement
Advertisement
Advertisement
x
About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.